News & Events

Dr Negrao on Olomorasib Plus Chemoimmunotherapy in KRAS G12C–Mutant NSCLC

Dr Negrao on Olomorasib Plus Chemoimmunotherapy in KRAS G12C–Mutant NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC?

How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC?

Dr Skoulidis on Emerging KRAS Inhibitors in NSCLC

Dr Skoulidis on Emerging KRAS Inhibitors in NSCLC

Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer

Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer

ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer

ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC